Westfield Capital Management
ACRS icon

Westfield Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Westfield Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-750,604
Closed -$15M – 250
2018
Q2 		$15M Buy
750,604
+40,235
+6% +$743K 0.11% 194
2018
Q1 		$12.4M Sell
710,369
-90,000
-11% -$1.91M 0.1% 193
2017
Q4 		$19.7M Sell
800,369
-291,575
-27% -$7.1M 0.15% 186
2017
Q3 		$28.2M Sell
1,091,944
-157,310
-13% -$4.22M 0.22% 152
2017
Q2 		$33.9M Buy
1,249,254
+553,752
+80% +$15.1M 0.29% 120
2017
Q1 		$20.7M Buy
695,502
+247,287
+55% +$7.13M 0.18% 167
2016
Q4 		$12.2M Buy
+448,215
New +$11.4M 0.11% 205

Other funds holding ACRS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Westfield Capital Management's ACRS Position: Q3 2018 in Review

Westfield Capital Management sold out of Aclaris Therapeutics (ACRS) in Q3 2018, closing a stake of 750,604 shares — an estimated $15M sold.

Westfield Capital Management first reported a position in ACRS in Q4 2016 and held it in 7 quarters. The position peaked at $33.9M in Q2 2017. 86 funds tracked by Wall St. Rank hold ACRS as of Q3 2018.

  • Westfield Capital Management reported no remaining Aclaris Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Westfield Capital Management sold 750,604 Aclaris Therapeutics shares in Q3 2018, an estimated $15M.
  • Westfield Capital Management first reported a position in Aclaris Therapeutics in Q4 2016 and held it in 7 quarters.
  • Westfield Capital Management's Aclaris Therapeutics position peaked at $33.9M in Q2 2017.
  • 86 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2018.

Based on Westfield Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.